IDEXX LABORATORIES INC /DE Payments of Merger Related Costs, Financing Activities
IDEXX LABORATORIES INC /DE (IDXX) reported Payments of Merger Related Costs, Financing Activities of $1.27 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities · last filed 2019-02-15
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for the quarter ending 2016-12-31 was $1.09M.
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for the quarter ending 2016-09-30 was $916.00K.
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for the quarter ending 2016-06-30 was $633.00K.
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for the quarter ending 2016-03-31 was $2.08M.
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for fiscal 2018 was $1.27M.
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- IDEXX LABORATORIES INC /DE payments of merger related costs, financing activities for fiscal 2016 was $4.73M.
| Period end | Payments of Merger Related Costs, Financing Activities 3 month | Payments of Merger Related Costs, Financing Activities 6 month | Payments of Merger Related Costs, Financing Activities 9 month | Payments of Merger Related Costs, Financing Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $1.27M 10-K · filed 2019-02-15 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-15 | |||
| 2016-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $2.01M derived: sum of 2 quarters · filed 2019-02-15 | $2.64M derived: sum of 3 quarters · filed 2019-02-15 | $4.73M 10-K · filed 2019-02-15 |
| 2016-09-30 | $916.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $1.55M derived: sum of 2 quarters · filed 2017-10-31 | $3.63M 10-Q · filed 2017-10-31 | |
| 2016-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $2.72M 10-Q · filed 2017-08-01 | ||
| 2016-03-31 | $2.08M 10-Q · filed 2017-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |